Omeza Receives FDA Clearance for Omeza® Collagen Matrix

Business

Image courtesy of Omeza

Omeza, a Sarasota-based skin science company, announced recently the U.S. Food and Drug Administration (FDA) cleared Omeza® Collagen Matrix through the FDA 510(k) premarket notification process. Omeza® Collagen Matrix is Omeza’s first Rx product, and the first drug/device combination matrix of its kind for chronic wound care.

“No one is taking on the challenge of making advanced wound care products both effective and affordable, yet preventable amputations are on the rise. We are determined to bridge that gap,” said Sarah Kitlowski, President of Omeza. “Our mission is to give practitioners groundbreaking new tools to help protect and manage the wound during the natural processes of wound closure.”

Omeza® Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant, and other plant-derived oils and waxes. When applied to a wound surface, the matrix is naturally incorporated into the wound over time. Omeza® Collagen Matrix is designed for intimate contact with both regular and irregular wound beds to provide a conducive environment for the patient’s natural wound healing process. The product features a no-prep application supplied in easy-to-use, unit dose vials.

Inquiries from medical and health professionals should be directed to info@omezapro.com.

Image courtesy of Omeza

« View The Monday Sep 6, 2021 SRQ Daily Edition
« Back To SRQ Daily Archive

Read More

Children and Families Strengthened through $50,000 Gift

Children and Families Strengthened through $50,000 Gift

Aug 12, 2022

SMH-Venice Welcomes 100th Baby Born Since Opening

SMH-Venice Welcomes 100th Baby Born Since Opening

Jul 19, 2022

New Procedure Available in Sarasota for Complex Digestive Conditions

New Procedure Available in Sarasota for Complex Digestive Conditions

Jul 8, 2022

Turtles Take Care

Turtles Take Care

Dylan Campbell | Jul 6, 2022